Abstract：
:Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer.
journal_name
Trends Cancerjournal_title
Trends in cancerauthors
Wennerberg E,Galluzzi Ldoi
10.1016/j.trecan.2018.12.005subject
Has Abstractpub_date
2019-03-01 00:00:00pages
143-145issue
3eissn
2405-8033issn
2405-8025pii
S2405-8033(19)30001-9journal_volume
5pub_type
信件相关文献
Trends in Cancer文献大全abstract：:The liver is one of the major metabolic organs in the body, susceptible to injury caused by various factors. In response to injury, sophisticated mechanisms are engaged to repair and regenerate the damaged liver, preventing its failure. When the damage is chronic, regeneration goes awry, impairing liver function and c...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.08.005
更新日期：2021-01-01 00:00:00
abstract：:The Abelson (ABL) tyrosine kinases were identified as drivers of leukemia in mice and humans. Emerging data has shown a role for the ABL family kinases, ABL1 and ABL2, in the progression of several solid tumors. This review will focus on recent reports of the involvement of the ABL kinases in tumor progression using m...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2015.07.004
更新日期：2015-10-01 00:00:00
abstract：:Cancer of unknown primary (CUP) is a rare malignancy that presents with metastatic disease and no identifiable site of origin. Most patients have unfavorable features and attempts to treat based on tissue-of-origin identification have not yielded a survival advantage compared with empiric chemotherapy. Next-generation...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.11.002
更新日期：2021-01-27 00:00:00
abstract：:Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to devel...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2016.07.002
更新日期：2016-08-01 00:00:00
abstract：:The tumor microenvironment has an essential role in defining tumor malignancy, since it can either promote or prevent tumor initiation and subsequent progression and metastatic dissemination. Recent studies demonstrate that highly aggressive cancer cells display a high degree of metabolic plasticity paralleled by the ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.11.001
更新日期：2016-12-01 00:00:00
abstract：:The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor cha...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.03.009
更新日期：2018-05-01 00:00:00
abstract：:The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized d...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.12.004
更新日期：2018-02-01 00:00:00
abstract：:Prediction of long-term outcomes from short-term measurements remains a fundamental challenge. Quantitative assessment of signaling dynamics, and the resulting transcriptomic and proteomic responses, has yielded fundamental insights into cellular outcomes. However, the utility of these measurements is limited by their...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.12.008
更新日期：2021-01-12 00:00:00
abstract：:The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct mole...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2016.04.003
更新日期：2016-05-01 00:00:00
abstract：:The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. T...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.03.008
更新日期：2016-05-01 00:00:00
abstract：:Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.09.010
更新日期：2019-11-01 00:00:00
abstract：:Dysregulation of the PI3K/PTEN pathway is a frequent event in cancer, and PIK3CA and PTEN are the most commonly mutated genes after TP53. PIK3R1 is the predominant regulatory isoform of PI3K. PIK3R2 is an ubiquitous isoform that has been so far overlooked, but data from The Cancer Genome Atlas shows that increased exp...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.02.009
更新日期：2019-04-01 00:00:00
abstract：:Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.04.010
更新日期：2020-08-01 00:00:00
abstract：:Traditionally, the efficacy of novel cancer therapies has been confirmed in patients failing regular treatment before being tested in early disease. Improved understanding of the mechanisms guiding therapeutic efficacy may challenge this dogma, suggesting novel therapies to move into early evaluation based on biologic...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.11.010
更新日期：2020-12-22 00:00:00
abstract：:Phosphoinositide 3-kinase (PI3K) generation of PI(3,4,5)P3 from PI(4,5)P2 and the subsequent activation of Akt and its downstream signaling cascades (e.g. mTORC1) dominates the landscape of phosphoinositide signaling axis in cancer research. However, PI(4,5)P2 is breaking its boundary as merely a substrate for PI3K an...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.05.009
更新日期：2016-07-01 00:00:00
abstract：:The identification of STING as a key cytoplasmic innate recognition molecule for DNA viruses whose function is lost in a variety of cancers has coincided with the approval of IMLYGIC for metastatic melanoma. This represents the first replication competent viral therapy approved for the treatment of any cancer in the U...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.01.002
更新日期：2016-02-01 00:00:00
abstract：:Obesity has been associated with increased severity of diagnoses for several types of cancer, and recent evidence suggests that the mechanism by which obese tissues contribute to cancer progression involves the extracellular matrix (ECM). Understanding the physicochemical differences between lean and obese ECM, and ho...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.02.001
更新日期：2018-04-01 00:00:00
abstract：:In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.05.014
更新日期：2020-09-01 00:00:00
abstract：:The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific research is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing still faces important financial and regulatory hurdles...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2017.06.007
更新日期：2017-08-01 00:00:00
abstract：:GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.07.005
更新日期：2019-09-01 00:00:00
abstract：:Alternative lengthening of telomeres (ALT) is an enigmatic process that allows certain cancers to maintain telomeres in the absence of telomerase. ALT cancers are frequently defective for ATRX/DAXX, a chaperone complex that deposits histone variant H3.3 at telomeres. We propose that mutations in alpha thalassemia-ment...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.02.003
更新日期：2016-03-01 00:00:00
abstract：:Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.07.002
更新日期：2018-09-01 00:00:00
abstract：:The survival rate of reproductive-age patients with cancer is increasing, reflecting the advent of better and more efficient therapies. Cancer survivors seek the resumption of a normal and healthy life, which often includes starting a family. Unfortunately, many cancer treatments increase the risk of premature ovarian...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.03.006
更新日期：2016-05-01 00:00:00
abstract：:Precision medicine requires appropriate application of genomics in clinical practice. In cancer, we have witnessed practice-changing examples of how genomic knowledge is translated into more tailored and effective therapies. The next opportunity is to embed cancer genomics in clinical context so that patient-centric l...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2015.07.010
更新日期：2015-09-01 00:00:00
abstract：:Cancers develop within complex tissue environments consisting of diverse innate and adaptive immune cells, along with stromal cells, vascular networks, and many other cellular and noncellular components. The high heterogeneity within the tumor microenvironment (TME) remains a key obstacle in understanding and treating...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.02.022
更新日期：2020-07-01 00:00:00
abstract：:Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer, metastasis formation and chemoresistance, and therefore represents an attractive target in oncology. However, direct targeting of EMT effector molecules is, in most cases, pharmacologically challenging. Since emerging research ha...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.06.005
更新日期：2020-11-01 00:00:00
abstract：:In a recent article, Bisogno et al. reported in a randomized trial that addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with rhabdomyosarcoma resulted in a significant increase in overall and event-free survival. Although the mechanism of action remains to be fully ...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2019.10.004
更新日期：2019-12-01 00:00:00
abstract：:Cadherins are key components in tissue morphogenesis and architecture, contributing to the establishment of cohesive cell adhesion. Reduced cellular adhesiveness as a result of cadherin dysfunction is a defining feature of cancer. During tumor development and progression, major changes in the glycan repertoire of canc...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.08.003
更新日期：2016-09-01 00:00:00
abstract：:Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating ch...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.09.004
更新日期：2017-11-01 00:00:00
abstract：:Although immunotherapy has proved to be effective in a variety of cancer subtypes, the role of immune checkpoint inhibition in the treatment of prostate cancer remains unclear. Here we review results from the latest clinical trials and discuss data suggesting that certain genetic mutations may confer increased sensiti...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.01.003
更新日期：2020-03-01 00:00:00
